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Abstract: Previous data from our laboratory have indicated that there is a functional link between the beta-adrenergic 
receptor signaling pathway and the G-protein inwardly rectifying potassium channel (GIRK1) in breast cancer cell lines 
and that these pathways are involved in growth regulation of these cells. To determine functionality, MDA-MB-453 breast 
cancer cells were stimulated with ethanol, known to open GIRK channels. Decreased GIRK1 protein levels were seen after 
treatment with 0.12% ethanol. In addition, serum-free media completely inhibited GIRK1 protein expression. This data 
indicates that there are functional GIRK channels in breast cancer cells and that these channels are involved in cellular 
signaling. In the present research, to further deﬁ  ne the signaling pathways involved, we performed RNA interference (siRNA) 
studies. Three stealth siRNA constructs were made starting at bases 1104, 1315, and 1490 of the GIRK1 sequence. These 
constructs were transfected into MDA-MB-453 cells, and both RNA and protein were isolated. GIRK1, β2-adrenergic and 
18S control levels were determined using real-time PCR 24 hours after transfection. All three constructs decreased GIRK1 
mRNA levels. However, β2 mRNA levels were unchanged by the GIRK1 knockdown. GIRK1 protein levels were also 
reduced by the knockdown, and this knockdown led to decreases in beta-adrenergic, MAP kinase and Akt signaling.
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Introduction
Breast cancer is the most frequently diagnosed cancer in women and the second leading cause of cancer 
death for women (American Cancer Society, 2007). There were an estimated 178,480 new cases of 
invasive breast cancer in 2007 in the U.S.A., making breast cancer responsible for 26% of new cancers 
(American Cancer Society, 2007). Worldwide, an estimated 1 million new cases occur each year, with 
a higher incidence in Western countries (Baselga and Norton, 2002). Established risk factors for breast 
cancer include age, increased hormone exposure, estrogen, alcohol consumption, and family history, 
as well as many other factors (Baselga and Norton, 2002). Approximately 40% of primary human breast 
cancer tissues have shown expression of mRNA that encodes a G-protein-coupled inwardly rectifying 
potassium channel (GIRK1), and this expression of GIRK1 was associated with a more aggressive 
clinical behavior (Stringer et al. 2001). Previous data from our laboratory has indicated that a functional 
link exists between the GIRK1 channel and the beta-adrenergic receptor pathway in breast cancer cell 
lines, and these pathways were involved in growth regulation of these cells (Cakir et al. 2002; Plummer 
et al. 2004). The estrogen receptor positive (ER (+)) cell lines MCF-7, MDA-MB-361, and ZR-75-1 
and the ER negative (−) cell line MDA-MB-453 expressed mRNA for the GIRK1 channel while the 
ER (−) cell lines MDA-MB-468 and MDA-MB-435S did not express GIRK1 (Plummer et al. 2004). 
Gene expression data indicated that mRNA for GIRK2 was observed in all cell lines except ZR-75-1 
and MDA-MB-435S and indicated that mRNA for GIRK4 was also observed in all cell lines (Plummer 
et al. 2004).
GIRK protein expression was also identiﬁ  ed in breast cancer cell lines. Expression of GIRK1 at the 
indicated molecular weight (MW) (62 kDa) was seen in cell lines MDA-MB-453 and ZR-75-1 (Dhar 
and Plummer, 2006). In addition, GIRK1 expression was seen at a lower MW (40–42 kDa) in 26
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MDA-MB-361, MDA-MB-468, MCF-7, ZR-75-1, 
and MDA-MB-453 cell lines. GIRK2 expression 
was seen in MDA-MB-453, MDA-MB-468, 
MCF-7, and ZR-75-1, while GIRK4 protein expres-
sion was seen in all six cell lines tested. Both 
GIRK2 and GIRK4 were at the indicated MW (Dhar 
and Plummer, 2006). This was the ﬁ  rst report indi-
cating GIRK protein expression in breast cancer 
cells and the ﬁ  rst report of GIRK protein expression 
outside its normal tissues of origin (heart and brain). 
Ethanol has been found to open G-protein inwardly 
rectifying potassium channels (GIRKs) in both 
heart and brain cells (Kobayashi et al. 1999). In 
addition, treatment of MCF-7 breast cancer cells 
with ethanol increased ERK1/2 activities and 
resulted in subsequent increased cell growth 
(Izevbigie et al. 2002). To determine functionality 
of GIRK channels in breast cancer cells, MDA-
MB-453 cells were stimulated with ethanol in our 
research. Decreased GIRK1 protein levels were 
seen after treatment with 0.12% ethanol in MDA-
MB-453 breast cancer cells (Dhar and Plummer, 
2006). Transfection of GIRK1 or GIRK4 plasmids 
increased GIRK1 protein expression and decreased 
gene expression in MDA-MB-453 breast cancer 
cells (Dhar and Plummer, 2006). This previous data 
indicates that functional GIRK channels exist in 
breast cancer cells and that they are involved in 
cellular signaling (Dhar and Plummer, 2006).
Serum-free media also decreased GIRK protein 
expression, possibly due to lack of estrogen in the 
media (Dhar and Plummer, 2006). Previous research 
has indicated that estrogen may have effects on 
potassium channels. Specifically, activation of 
potassium channels may be involved in the effects 
of 17-β-estradiol in rat mesenteric artery rings 
(Tsang et al. 2003). In addition, 17-β-estradiol can 
modulate GIRK channel activation in the brain, and 
this modulation is blocked by protein kinase A 
(PKA) and protein kinase C (PKC) inhibitors (Kelly 
et al. 2003). Estrogen induced a rapid and irrevers-
ible augmentation of potassium currents in MCF-7 
cells (Coiret et al. 2005). Two potassium channel 
blockers (amiodarone and dequalinium) also poten-
tiated the growth inhibitory effects of the breast 
cancer drug tamoxifen in two breast cancer cell 
lines (Abdul et al. 2003). If estrogen affects potas-
sium channels, then blockage of potassium channels 
would be a different and innovative method for 
cancer treatment, especially in ER (−) tumors.
To further deﬁ  ne the signaling pathways involved, 
we performed RNA interference (siRNA) studies on 
ER (−) MDA-MB-453 cells, which we have used 
extensively in previous research in our laboratory. 
RNA interference is a more effective and efﬁ  cient 
technique for gene knockdown than other techniques 
(Cullen, 2006). This technique could also possibly 
be used for drug development in cancer (Mousses, 
2003). Our previous research has used the MDA-
MB-453 cell line (Cakir et al. 2002; Plummer et al. 
2004; Dhar and Plummer, 2006), so these siRNA 
experiments were performed in this cell line for 
consistency. Multiple investigators have used one 
breast cancer cell line for RNA interference studies 
(Zivadinovic et al. 2005; Santra et al. 2000; Lu and 
Serrero, 2001). In this study, three stealth siRNA 
constructs were transfected into the MDA-MB-453 
breast cancer cell line, and protein was isolated. 
GIRK1 knockdown led to decreases in β-adrenergic, 
MAP kinase and Akt signaling.
Materials and Methods
Cell culture
The human estrogen non-responsive MDA-MB-453 
breast cancer cell line was purchased from the Amer-
ican Type Culture Collection (Rockville, MD, U.S.A.) 
and was maintained in RPMI 1640 medium supple-
mented with fetal bovine serum (10%, v/v), L-
glutamine (2 mM), 100 U/ml penicillin, and 100 µg/ml 
streptomycin at 37 °C in an environment of 5% CO2.
Real-time PCR
RNA isolation and real-time PCR were done as 
previously described (Plummer et al. 2004, 2005). 
Brieﬂ  y, real-time PCR was done using the Cepheid 
smart cycler. The GIRK1 primers for real-time 
PCR are forward 5´-ctctcggacctcttcaccac-3´ 
and reverse 5´-gccacggtgtaggtgagaat-3´ (bases 
398–477, Genbank Accession # NM_002239), and 
the internal TaqMan probe is 6-FAM-tcaagtggc-
gctggaacctc-TAMRA (bases 429–449). The 
real-time PCR conditions for GIRK1 were 95 °C 
for 120 seconds, followed by 45 cycles of 
95 °C, 15 seconds; 62 °C, 10 seconds; and 
72 °C, 15 seconds. 18S rRNA detection reagents 
(Eurogentec, San Diego, CA, U.S.A.) were used 
for normalization of the data.
siRNA
Three stealth siRNA constructs (Invitrogen, Carlsbad, 
CA, U.S.A.) were made starting at bases 1104, 1315, 27
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and 1490 of the GIRK1 sequence (GenBank # 
NM_002239). These constructs are: 1104 sense─gga 
aac aac ugg gau gac uug uca a; 1104 antisense─uug 
aca agu cau ccc agu ugu uuc c (GC content 44%); 
1315 sense─cca gcc aua acu aac agc aaa gaa a; 1315 
antisense─uuu cuu ugc ugu uag uua ugg cug g (GC 
content 40%); 1490 sense─acu ugc cca uga aac uuc 
aac gaa u; 1490 antisense─auu cgu uga agu uuc aug 
ggc aag u (GC content 40%). In addition, the low GC 
RNAi negative control (35%–45% GC) was used as 
recommended by the manufacturer (Invitrogen). 
These constructs (200 pMol) were transfected into 
the MDA-MB-453 breast cancer cell lines using 
lipofectamine 2000 (Invitrogen).
Western blots
Cells were harvested, and membrane and total 
proteins were isolated as previously described 
(Plummer et al. 2004, 2005; Dhar and Plummer, 
2006). Antibodies for GIRK1 (Lifespan Biosci-
ences, Seattle, WA, U.S.A.), β2 (Santa Cruz, Santa 
Cruz, CA, U.S.A.), CREB, phosphoCREB (Upstate, 
Lake Placid, NY, U.S.A.), Akt, phosphoAkt, ERK, 
and phosphoERK (Cell Signaling, Danvers, MA, 
U.S.A.) were used in these studies. Immunoblot 
analysis was carried out using standard procedures 
as described previously (Plummer et al. 2004, 2005; 
Dhar and Plummer, 2006). Brieﬂ  y, 20 µg of proteins 
were resolved on 12% SDS-PAGE, transferred to 
nitrocellulose membranes, blocked for 1 hour, and 
immunoblotted overnight with the speciﬁ  c primary 
antibodies. Primary antibodies were detected with 
horseradish peroxidase-coupled secondary antibody 
and enhanced chemiluminescence (Pierce, Rock-
ford, IL, U.S.A.). In all Western blots, membranes 
were additionally probed with an antibody for 
GAPDH (Santa Cruz) to ensure equal loading of 
protein between samples. GAPDH has been previ-
ously used as a loading control (Hambsch et al. 
2005). Actin was not used because GIRKs may 
affect actin (Huang et al. 1998; Nikolov and Iva-
nova-Nikolova, 2004). Protein bands on the immu-
noblots were quantitated using Scion Image 
software, release Alpha 4.0.3.2 (http://www.
scioncorp.com) using three separate measurements 
of each band on the gel.
Results
Three stealth siRNA constructs (Invitrogen) were 
made starting at bases 1104, 1315, and 1490 of the 
GIRK1 sequence (GenBank # NM_002239) to 
knockdown GIRK1 levels in the MDA-MB-453 
breast cancer cell line used extensively in previous 
research in our laboratory (Plummer et al. 2004; 
Dhar and Plummer, 2006). These constructs were 
transfected into MDA-MB-453, and RNA was 
isolated 24 hours after transfection. GIRK1, 
β2-adrenergic and 18S control levels were deter-
mined using real-time PCR. All three constructs 
noticeably decreased GIRK1 mRNA levels (Fig. 1). 
Data are presented as GIRK1 CT value minus 18S 
CT value (n = 2): control: 15.9; 1104: 17.93 (88.6% 
of corrected control CT); 1315: 17.60 (90.3% of 
corrected control CT); and 1490: 18.63 (85.3% of 
corrected control CT).  However, β2 mRNA levels 
were unchanged by the GIRK1 knockdown (data 
not shown).
These three siRNA constructs were also trans-
fected into additional MDA-MB-453 cells, and 
protein was isolated after 24 hours, 3 days and 5 
days after transfection.  Enriched membrane pro-
tein was isolated, Western blotting was performed, 
and the membranes were probed with antibodies 
to GIRK1. All three siRNA constructs reduced 
GIRK1 protein levels 24 hours after transfection 
(Fig. 2). At 24 hours, the GIRK1 protein levels 
were 57.1% of control levels for the 1104 construct, 
41.2% of control levels for the 1315 construct and 
52.1% of control levels for the 1490 construct. 
These reductions were reversed by 3–5 days, and 
in the case of one construct, increased over control 
levels (Fig. 2). At 3 days, the GIRK1 protein levels 
were 109.7% of control levels for the 1104 con-
struct, 267.8% of control levels for the 1315 con-
struct and 78.1% of control levels for the 1490 
construct.   At 5 days, the GIRK1 protein levels 
were 99.0% of control levels for the 1104 construct, 
81.1% of control levels for the 1315 construct and 
178.8% of control levels for the 1490 construct. 
When the low GC RNAi negative control (Invit-
rogen) for the GIRK1 stealth siRNA was used, 
there were no effects on GIRK1 protein expression 
at either one, three or ﬁ  ve days (data not shown).
Total protein was also isolated from the GIRK1 
stealth siRNA transfections. Western blots under-
went electrophoresis with these proteins, and were 
probed for possible cell signaling pathways that 
may be affected by GIRK. Our laboratory has 
previously indicated a correlation between GIRK 
expression and β-adrenergic signaling (Cakir et al. 
2002; Plummer et al. 2004). Activation of the beta-
adrenergic signaling pathway may lead to phos-
phorylation of the cAMP-response element binding 28
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protein (CREB) (Daniel et al. 1999). We also 
wanted to look at other cellular pathways that we 
hypothesize could be involved in GIRK signaling, 
such as the MAP kinase pathway or the Akt path-
way. In examining these pathways, we found that 
β2-adrenergic protein expression was reduced from 
control levels from 1–5 days (Fig. 3).  β2-adrenergic 
phosphorylation was increased at 1 day, but 
reduced at 3 days and 5 days by all three constructs 
(data not shown). CREB protein expression was 
reduced by two siRNA constructs at 1 day and 3 
days, but only one construct at 5 days (Fig. 3). 
CREB phosphorylation was reduced by all con-
structs at 1 day and 5 days, but increased by one 
construct at 3 days (Fig. 3). This data conﬁ  rms our 
previous data that the β-adrenergic signaling 
pathway is correlated with GIRK expression (Cakir 
et al. 2002; Plummer et al. 2004). ERK protein 
expression was reduced at 1 day and 3 days by all 
constructs, but increased by one construct at 5 days 
(Fig. 3). ERK phosphorylation was increased by 
one construct (1104) at 1 day, but reduced by the 
other two constructs; reduced by the same two 
constructs at 3 days; and increased by the same 
two constructs at 5 days (Fig. 3). Akt protein 
expression was reduced by all constructs at 1 day 
and 3 days, but only one construct at 5 days. Akt 
phosphorylation was reduced at 1 day and 3 days, 
but increased at 5 days for all constructs (Fig. 3). 
These data indicate that both MAP kinase signaling 
Control
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Figure 1. Real-time PCR of MDA-MB-453 cells transfected with GIRK1 stealth siRNA. MDA-MB-453 breast cancer cells were transfected 
with 3 stealth siRNA constructs starting at bases 1104, 1315, and 1490 of the GIRK1 sequence (GenBank # NM_002239) (Invitrogen). RNA was 
isolated 24 hours after transfection and cDNA was made. (A) Real-time PCR graph of MDA-MB-453 cells transfected with three GIRK1 siRNA 
constructs (1104, 1315, 1490). All three siRNA constructs produced noticeable GIRK1 gene knockdown. Numbers to the right of graph indicate 
the three separate constructs. (B) Real-time PCR graph of 18S genomic control levels of MDA-MB-453 cells transfected with three GIRK1 siRNA 
constructs. No changes were noted in 18S levels indicating that the changes seen in graph (A) are due to the experimental effects. These are 
graphs representative of two separate experiments. None of the constructs altered β-adrenergic gene expression (data not shown).29
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and Akt signaling may be involved in responses 
to GIRK.
Discussion
In the present study, GIRK1 mRNA and protein 
expression both were reduced by use of stealth 
siRNA for GIRK1. This is the ﬁ  rst time GIRK1 
knockdown by use of RNA interference has been 
reported in the literature. This data supports our 
previous results that there are functional GIRK 
channels in breast cancer cell lines (Cakir et al. 
2002; Plummer et al. 2004; Dhar and Plummer, 
2006). Our previous research has repeatedly used 
the MDA-MB-453 ER (−) cell line (Cakir et al. 
2002; Plummer et al. 2004; Dhar and Plummer, 
2006), so these siRNA experiments were per-
formed in this cell line for consistency. ER (−) 
breast cancers have a poorer prognosis than ER (+) 
cancers (Nagai et al. 1994; Lemieux et al. 1996). 
Overexpression of GIRK1 mRNA has been identi-
ﬁ  ed in tissue samples from approximately 30% of 
primary human breast cancers tested (Stringer et al. 
2001), and this over-expression of GIRK1 was 
associated with a more aggressive clinical behav-
ior. Therefore, we believe that the MDA-MB-453 
cell line is appropriate for these siRNA studies, 
because their use aids to further elucidate signal 
differences in ER (−) cancers.
Previous data from our laboratory established 
a functional link between β-adrenergic signaling 
and GIRK channels in breast cancer (Cakir et al. 2002; 
Figure 2. GIRK1 protein expression of MDA-MB-453 cells transfected with GIRK1 stealth siRNA. MDA-MB-453 breast cancer cells 
were transfected with 3 stealth siRNA constructs (Invitrogen). Enriched membrane protein was isolated 1, 3, and 5 days after transfection 
by the ReadyPrep protein extraction kit (signal) (Bio-Rad, Richmond, CA, U.S.A). Western blotting was performed, and the membranes were 
probed with antibodies to GIRK1 and GAPDH. (A) Western blots indicating GIRK1 and GAPDH expression of MDA-MB-453 cells transfected 
with three GIRK1 siRNA constructs (1104, 1315, 1490). Samples were collected at 24 hours, 3 days and 5 days. (B) Graphs indicate den-
sitometry of the Western blots. The densitometry of GIRK1 was divided by the densitometry of the control GAPDH (N = 3). All three siRNA 
constructs reduced GIRK1 protein levels 24 hours after transfection. These reductions were reversed by 3-5 days, and in the case of one 
construct, increased over control levels. The bands are consistent with the expected size: GIRK1 (40–42 kDa; Dhar and Plummer 2006); 
GAPDH (37 kDa). These are gels representative of two separate experiments.
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Plummer et al. 2004). Increases in GIRK currents 
by β-adrenergic stimulation have been reported in 
adult rat cardiomyocytes and in Xenopus laevis 
oocytes coexpressing β2-adrenergic receptors and 
GIRK1/GIRK4 subunits (Mullner et al. 2000). In 
addition, in rat atrial myocytes transiently trans-
fected with β1 or β2 adrenergic receptors, the β-
adrenergic agonist isoproterenol stimulated GIRK 
currents, whereas this stimulation was not seen in 
non-transfected cells (Wellner-Kienitz et al. 2001). 
Activation of the β-adrenergic signaling pathway 
(a prototypic G-protein-coupled receptor (GPCR); 
Whalen et al. 2007) can lead to phosphorylation 
of CREB (Daniel et al. 1999). In the present stud-
ies, reductions in GIRK1 mRNA and protein 
expression lead to reductions in the β-adrenergic 
signaling pathway as evidenced by decreases in 
β2-adrenergic levels and CREB protein levels, 
conﬁ  rming and expanding other data from our 
laboratory (Cakir et al. 2002; Plummer et al. 2004; 
Dhar and Plummer, 2006). The present studies also 
indicated that there were no effects of GIRK1 
siRNA knockdown on β2-adrenergic mRNA 
expression. It is our hypothesis that the beta-
adrenergic system is potentially reduced through 
non-genomic pathways. Previous investigators 
have shown that 1 alpha, 25-dihydroxy-vitamin 
D3 effects on cardiac muscle calcium influx 
involves non-genomic modulation of the beta-
adrenergic signaling pathway (Santillan et al. 
1999). In addition, there are non-genomic actions 
of 17 beta-estradiol on opening Ca
2+- and voltage-
activated potassium channels in lacrimal acinar 
cells (Suzuki et al. 2004). Maxi-potassium channels 
are also activated through a non-genomic pathway 
in MCF-7 breast cancer cells (Coiret et al. 2005). 
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Figure 3. Protein expression of components of cell signaling pathways in MDA-MB-453 cells transfected with GIRK1 stealth siRNA. 
MDA-MB-453 breast cancer cells were transfected with 3 stealth siRNA constructs (Invitrogen). Total protein was isolated 1, 3, and 5 days 
after transfection by RIPA. Western blotting was performed, and the membranes were probed with antibodies to the intermediates in the 
signaling pathways. (A) Western blots indicating β2-adrenergic, CREB, phosphoCREB, Akt, PhosphoAkt, ERK, phosphoERK and GAPDH 
expression of MDA-MB-453 cells transfected with three GIRK1 siRNA constructs (1104, 1315, 1490). Samples were collected at 24 hours, 
3 days and 5 days. (B) Graphs indicate densitometry of the Western blots. The densitometry of signaling proteins being measured were 
standardized by dividing the densitometry of the control GAPDH (N = 3). Data were analyzed by ANOVA followed by the Tukey test. *indicates 
p  0.05 from control. β2-adrenergic protein expression was reduced from control levels at all three time periods. β2-adrenergic phosphory-
lation was increased at 24 hours, but reduced at 3 days and 5 days by all three constructs (data not shown). CREB protein expression was 
reduced by two siRNA constructs at 24 hour (1104,1490) and 3 day (1104,1315), but only one construct at 5 days (1315). CREB phos-
phorylation was reduced by all constructs at 24 hours and 5 days, but increased by one construct at 3 days (1315). Akt protein expression 
was reduced by all constructs at 24 hours and 3 days, but only one construct at 5 days (1315). Akt phosphorylation was reduced at 24 hours 
and 3 days, but increased at 5 days for all constructs. ERK protein expression was reduced at 24 hours and 3 days by all constructs, but 
increased by one construct at 5 days (1104). ERK phosphorylation was increased at 24 hours (1104), but reduced by the other two constructs; 
reduced by two constructs at 3 days (1315, 1490); and increased by two constructs at 5 days (1315,1490). The bands are consistent with 
the expected size: β2 (68 kDa); CREB/pCREB (43 kDa); Akt/pAkt (60 kDa); ERK/pERK (42–44 kDa); GAPDH (37 kDa). These are gels 
representative of two separate experiments.
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Further research is needed in order to determine the 
non-genomic mechanism of beta-adrenergic 
reduction by GIRK1.
We wanted to investigate whether this reduction 
of GIRK protein levels, possibly mediated through 
the β2-adrenergic GPCR pathway, has effects on 
other cellular signaling pathways that have been 
seen in cancer progression. A recent review indi-
cated that many of the transforming events in breast 
cancer could be mediated by Akt signaling (Liu 
et al. 2007). In addition, the tobacco carcinogen 
4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone 
(NNK) has been shown to stimulate cell prolifera-
tion mediated through Akt signaling (Tsurutani 
et al. 2005). Our previous work has also indicated 
that NNK activates the β-adrenergic GPCR 
signaling pathway in this MDA-MB-453 cell line 
(Hance et al. 2006). In the present studies, both 
ERK and Akt protein levels and protein phos-
phorylation were reduced by GIRK1 knockdown. 
Akt phosphorylation was reduced at early time 
periods but increased at 5 days for all constructs 
(Fig. 3). In these studies, the data indicates that 
there is gene knockdown, followed by increases in 
protein expression. It also appears that there are 
differences in the activities of the three different 
constructs, and these differences appear to a greater 
degree 5 days after introduction of the siRNA 
constructs. It is apparent that in some cases these 
constructs either are no longer functioning at 5 
days, or that there is an over-compensation for 
some of the constructs.   A recent paper has indi-
cated that some of the differences in efﬁ  cacy of 
siRNA constructs may be due to accessibility to 
target sequences (Liao et al. 2008). It could be that 
after 5 days, the GIRK target has changed. Further 
research is needed in order to conﬁ  rm these hypoth-
eses. In other studies, GIRK channel inhibitors 
inhibited the platelet P2Y(12)-mediated increase 
in Akt phosphorylation (Shankar et al. 2004). Akt 
has been shown to be an important mediator in 
other potassium channels as well. Akt phosphory-
lation has been shown to be important in actions 
of ATP-sensitive potassium channels in rats (Goni-
Allo et al. 2007). In the present studies, we show 
a deﬁ  nitive correlation between GIRK function 
and Akt signaling in the MDA-MB-453 cell line, 
indicating that GIRK function could be correlated 
with a cellular signaling pathway that leads to cel-
lular transformation. Blockage of this pathway 
could then possibly have important therapeutic 
effects in ER (−) breast cancer. Other investigators 
have found that in MCF-7 breast cancer cells, 
insulin-like growth factor-1 increases both activity 
and expression of human ether-a-go-go potassium 
channels by stimulation of Akt (Borowiec et al. 
2007). These ether-a-go-go potassium channels 
were also found to be important in mediating cell 
proliferation in the MCF-7 cells (Borowiec et al. 
2007).
MAP kinase has been shown to be a critical 
mediator of breast cancer cell migration (Ostrander 
et al. 2007). In cerebellar granule neurons, high 
potassium levels resulted in sustained activation 
of MAP kinase, and additionally, insulin-like 
growth factor activated Akt (Zhong et al. 2004). 
These same high potassium levels also led to 
increases in CREB phosphorylation (Zhong et al. 
2004). Insulin-like growth factor has been shown 
to stimulate breast cancer cell migration (Zhang 
et al. 2005). In addition, blockage of the MAP 
kinase pathway in turn blocked the effects of 
PGE(2) on ROMK-like small conductance potas-
sium channels in the distal tubule segment cortical 
collecting duct cells (Jin et al. 2007). Similar inhi-
bition of Ca
2+-activated big conductance potassium 
channels was seen in distal tubule segment princi-
pal cells (Li et al. 2006). In the present studies, we 
show that responses to GIRK signaling in breast 
cancer are associated with MAP kinase signaling, 
indicating that GIRK function may be associated 
with a signaling pathway correlated with cell 
migration. This observation may offer a signiﬁ  cant 
therapeutic target, since expression of GIRK1 was 
associated with a more aggressive clinical behav-
ior in human breast cancer tissues (Stringer et al. 
2001). In addition, other investigators indicated 
that GIRK1 mRNA expression was associated with 
lymph node metastasis in tissue specimens from 
patients with non-small lung cancer. Further inves-
tigation is needed to indicate if breast cancer 
metastasis stimulated by GIRK is mediated by 
MAP kinase, and is correlated with the clinical 
aggressiveness of ER (−) breast cancer.
A recent review has indicated that potassium 
channels may be valuable in cancer therapy (Conti, 
2004). Others have indicated that a combination 
therapy of tamoxifen and potassium channel 
blockers may be important in treatment of breast 
cancer due to the effects of potassium channels on 
increasing breast cancer cell proliferation (Abdul 
et al. 2003). In addition, small conductance Ca
2+-
activated potassium channels may mediate breast 
cancer cell migration (Potier et al. 2006). 33
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Our results and those of others seem to indicate 
that blockage of GIRK channels may be important 
in breast cancer, and more work is needed to 
further elucidate the signaling pathways involved 
in GIRK signaling in breast cancer, and to indicate 
if the signaling pathways associated with 
these GIRK channels are involved in cancer 
progression and cell migration, as well as in cell 
proliferation.
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